Pfizer (PFE) Shares are Down -3.93%

Pfizer (PFE) : During the past 4 weeks, traders have been relatively bearish on Pfizer (PFE), hence the stock is down -4.26% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.34% relative to the S&P 500. The 4-week change in the price of the stock is -1.88% and the stock has fallen -3.93% in the past 1 week.

Pfizer (NYSE:PFE): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.36 and $35.22 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.53. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.44, notching a gain of 0.83% for the day. The total traded volume was 27,196,405 . The stock had closed at $35.15 on the previous day.

The stock has recorded a 20-day Moving Average of 2.19% and the 50-Day Moving Average is 0.61%. Pfizer Inc. is up 7.37% in the last 3-month period. Year-to-Date the stock performance stands at 12.82%.

Pfizer (PFE) has been rated by 13 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $54 and the lowest price target forecast is $33. The average forecast of all the analysts is $39.46 and the expected standard deviation is $5.39.


Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *